Skip to main content

Investors

Moberg Pharma’s share is listed on the main list at NASDAQ OMX Stockholm. Moberg Pharma’s goal is to create value and provide attractive shareholder returns through the successful commercialization of its pipeline assets.

In 2019, the focus is on advancing the company's phase 3 development programs and to continue commercialization preparations to maximize value and create future growth.

 

Aktiekurs 17 Jun 2013 14:30
33.90 kr
1.19 %

Calendar/presentations

Next calendar event: 2020-02-11 Interim report for July - December 2019

Contact Investor
relations:

Anna Ljung, CEO
Tel. +46 (0)8 522 307 01
Email: anna.ljung@mobergpharma.se

Peter Wolpert, Executive Chairman and Founder
Tel: +46 (0)8 522 307 08
Email: peter.wolpert@mobergpharma.se
 

 

Subscribe

Get our latest press releases and reports